Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 35Lymphoma, Follicular 30Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Pancreatic Neoplasms 15Neoplasm Metastasis 15Leukemia 15Squamous Cell Carcinoma of Head and Neck 12Melanoma 12Stomach Neoplasms 11Colorectal Neoplasms 11Lymphoma, B-Cell, Marginal Zone 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

fludarabine 2Interferon beta-1b 2Cyclophosphamide 2nabiximols 1Natalizumab 1Mn-PyC3A 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Sclerosis × Cyclophosphamide × Clear all
NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Gilead Sciences

Phase 1 Recruiting
52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1 Recruiting
120 enrolled

Multiple Sclerosis, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡